HYUNDAI PHARMACEUTICAL CO., LTD
004310 | KO
Overview
Corporate Details
- ISIN(s):
- KR7004310009
- LEI:
- Country:
- South Korea
- Address:
- 충청남도 천안시 동남구 풍세면 잔다리길 55, 천안시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 9.0 KB | ||
| 2025-07-14 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 14.8 KB | ||
| 2025-07-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.05)
|
Korean | 876.8 KB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 10.4 KB | ||
| 2025-04-28 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-14 00:00 |
Quarterly Report
분기보고서 (2025.02)
|
Korean | 827.4 KB | ||
| 2025-02-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 23.9 KB | ||
| 2025-02-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.8 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.9 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
[첨부추가]사업보고서 (2024.11)
|
Korean | 524.8 KB | ||
| 2025-02-12 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.9 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 109.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 6.1 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI PHARMACEUTICAL CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for HYUNDAI PHARMACEUTICAL CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI PHARMACEUTICAL CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Sweden
LIPI
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
United States of America
LPCN
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
United States of America
LQDA
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
United States of America
LSTA
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
United States of America
LGVN
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Switzerland
LONN
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
United States of America
LYEL
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
United States of America
LYRA
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Norway
LYTIX
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
Poland
MAB